AI Engines For more Details: Perplexity Kagi Labs You
Epilepsy: Carbamazepine is one of the first-line treatments for various types of epilepsy, including focal seizures (formerly known as partial seizures) and generalized tonic-clonic seizures (formerly known as grand mal seizures). It works by stabilizing neuronal membranes, reducing the excessive electrical activity that leads to seizures.
Trigeminal Neuralgia: Carbamazepine is also commonly used to treat trigeminal neuralgia, a type of neuropathic pain characterized by severe facial pain along the trigeminal nerve distribution. By suppressing abnormal nerve firing, carbamazepine can help alleviate the sharp, stabbing pain associated with this condition.
Bipolar Disorder: Carbamazepine is sometimes used as a mood stabilizer in the management of bipolar disorder, particularly in cases where lithium or other mood stabilizers are ineffective or poorly tolerated. It can help prevent manic and depressive episodes and stabilize mood fluctuations in individuals with bipolar disorder.
Other Neuropathic Pain Conditions: In addition to trigeminal neuralgia, carbamazepine may be prescribed off-label to manage other neuropathic pain conditions, such as diabetic neuropathy, postherpetic neuralgia, and radiculopathy (nerve root pain). Its mechanism of action in neuropathic pain involves modulation of voltage-gated sodium channels in the nervous system.
Safety Considerations: While generally effective, carbamazepine can cause a range of side effects, including dizziness, drowsiness, nausea, vomiting, blurred vision, ataxia, and cognitive impairment. Serious adverse effects may occur, such as severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), hematological abnormalities (e.g., leukopenia, thrombocytopenia), and liver toxicity. Regular monitoring of blood counts and liver function tests is often recommended during carbamazepine therapy.
Drug Interactions: Carbamazepine has a significant potential for drug interactions due to its induction of hepatic enzymes, particularly cytochrome P450 enzymes. It can accelerate the metabolism of many other medications, reducing their efficacy and necessitating dose adjustments. Conversely, certain drugs may inhibit the metabolism of carbamazepine, leading to increased plasma levels and potential toxicity.
Pregnancy and Breastfeeding: Carbamazepine may pose risks to pregnant individuals and their developing fetuses, including an increased risk of congenital malformations (e.g., neural tube defects) and developmental delays. However, the decision to continue or discontinue carbamazepine therapy during pregnancy should be carefully weighed based on individual clinical circumstances and the potential risks and benefits. Carbamazepine is excreted in breast milk and may cause adverse effects in breastfeeding infants.
Dosage and Administration: Carbamazepine is typically taken orally in tablet or liquid form. The dosage regimen varies depending on the patient's age, weight, medical condition, and response to treatment. It is important to follow the prescribing healthcare professional's instructions and undergo regular monitoring to ensure optimal therapeutic outcomes and minimize the risk of adverse effects.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Bilophila | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Mediterraneibacter | genus | Decreases |
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Fusobacterium | genus | Decreases |
0 | 1 | Shigella | genus | Decreases |
0 | 1 | Streptococcus | genus | Decreases |
0 | 1 | Parabacteroides | genus | Decreases |
0 | 1 | Segatella | genus | Decreases |
0 | 1 | Lacticaseibacillus | genus | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
1 | 0 | Bacteroides caccae | species | Decreases |
1 | 0 | Bilophila wadsworthia | species | Decreases |
1 | 0 | Mediterraneibacter gnavus | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
1 | 0 | Fusobacterium nucleatum | species | Decreases |
1 | 0 | Streptococcus salivarius | species | Decreases |
0 | 1 | Blautia argi | species | Decreases |
0 | 1 | Streptococcus sp. FDAARGOS_192 | species | Decreases |
0 | 1 | Shigella dysenteriae | species | Decreases |
1 | 0 | Parabacteroides merdae | species | Decreases |
0 | 1 | Shigella flexneri | species | Decreases |
0 | 1 | Escherichia albertii | species | Decreases |
0 | 1 | Escherichia fergusonii | species | Decreases |
0 | 1 | Alistipes sp. dk3624 | species | Decreases |
0 | 1 | Vescimonas coprocola | species | Decreases |
0 | 1 | Shigella boydii | species | Decreases |
0 | 1 | Dysosmobacter welbionis | species | Decreases |
0 | 1 | Alistipes indistinctus | species | Decreases |
0 | 1 | Pusillibacter faecalis | species | Decreases |
1 | 0 | Segatella copri | species | Decreases |
1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
ADHD | 0.3 | 0.3 | |
Age-Related Macular Degeneration and Glaucoma | 0.1 | -0.1 | |
Allergic Rhinitis (Hay Fever) | 1.1 | 0.4 | 1.75 |
Allergies | 1.4 | 0.6 | 1.33 |
Allergy to milk products | 0.7 | 0.6 | 0.17 |
Alzheimer's disease | 2.3 | 2.6 | -0.13 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.9 | 0.3 | 2 |
Ankylosing spondylitis | 1.2 | 0.9 | 0.33 |
Anorexia Nervosa | 0.2 | 1.2 | -5 |
Antiphospholipid syndrome (APS) | 0.4 | 0.4 | 0 |
Asthma | 1.8 | 0.5 | 2.6 |
Atherosclerosis | 1.5 | 1.5 | |
Atrial fibrillation | 1.2 | 1.3 | -0.08 |
Autism | 2.1 | 2.5 | -0.19 |
Autoimmune Disease | 0.3 | 0.3 | |
Barrett esophagus cancer | 0.1 | 0.1 | 0 |
benign prostatic hyperplasia | 0.3 | 0.4 | -0.33 |
Biofilm | 1 | 1 | |
Bipolar Disorder | 1.2 | 1.2 | |
Brain Trauma | 0.1 | 0.4 | -3 |
Breast Cancer | 0.6 | 0.6 | |
Cancer (General) | 0.1 | 0.6 | -5 |
Carcinoma | 1.5 | 0.5 | 2 |
Celiac Disease | 1.5 | 0.9 | 0.67 |
Cerebral Palsy | 0.5 | 0.4 | 0.25 |
Chronic Fatigue Syndrome | 1.3 | 1.3 | 0 |
Chronic Kidney Disease | 1.7 | 0.4 | 3.25 |
Chronic Lyme | 0.4 | -0.4 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.7 | 0.2 | 2.5 |
Chronic Urticaria (Hives) | 0.6 | 0.8 | -0.33 |
Coagulation / Micro clot triggering bacteria | 0.7 | 0.1 | 6 |
Cognitive Function | 0.6 | 0.1 | 5 |
Colorectal Cancer | 2.7 | 0.7 | 2.86 |
Constipation | 0.7 | 0.7 | |
Coronary artery disease | 1.1 | 1.1 | 0 |
COVID-19 | 1.4 | 1.9 | -0.36 |
Crohn's Disease | 3.2 | 1.3 | 1.46 |
Cushing's Syndrome (hypercortisolism) | 0.4 | -0.4 | |
cystic fibrosis | 0.5 | 0.4 | 0.25 |
d-lactic acidosis (one form of brain fog) | 0.3 | 0.3 | |
deep vein thrombosis | 1.5 | 0.5 | 2 |
Denture Wearers Oral Shifts | 0.5 | 0.5 | |
Depression | 3 | 1 | 2 |
Dermatomyositis | 0.1 | 0.1 | |
Eczema | 0.9 | 0.9 | 0 |
Endometriosis | 1.1 | 0.3 | 2.67 |
Eosinophilic Esophagitis | 0.1 | 0.1 | 0 |
Epilepsy | 1.9 | 0.6 | 2.17 |
erectile dysfunction | 0.8 | 0.8 | |
Fibromyalgia | 0.2 | 0.5 | -1.5 |
Functional constipation / chronic idiopathic constipation | 1.8 | 1.8 | 0 |
gallstone disease (gsd) | 1.6 | 0.1 | 15 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1 | 0.1 | 9 |
Generalized anxiety disorder | 1.6 | 0.5 | 2.2 |
Glioblastoma | 0.1 | -0.1 | |
Gout | 1.1 | 0.1 | 10 |
Graves' disease | 0.5 | 0.5 | 0 |
Gulf War Syndrome | 0.1 | 0.7 | -6 |
Halitosis | 0.9 | 0.1 | 8 |
Hashimoto's thyroiditis | 1.2 | 0.8 | 0.5 |
Heart Failure | 1.8 | 1.8 | |
hemorrhagic stroke | 0.2 | 0.2 | |
Hidradenitis Suppurativa | 1.1 | 1.1 | |
High Histamine/low DAO | 0.3 | 0.3 | |
hypercholesterolemia (High Cholesterol) | 0.3 | 0.3 | |
hyperglycemia | 0.8 | 0.5 | 0.6 |
Hyperlipidemia (High Blood Fats) | 0.4 | 0.4 | |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 1 | 1.6 | -0.6 |
Hypoxia | 0.5 | 0.5 | |
IgA nephropathy (IgAN) | 0.7 | 0.5 | 0.4 |
Inflammatory Bowel Disease | 2.9 | 2.3 | 0.26 |
Insomnia | 0.7 | 0.5 | 0.4 |
Intelligence | 0.7 | 0.1 | 6 |
Intracranial aneurysms | 0.6 | 0.6 | |
Irritable Bowel Syndrome | 2.6 | 0.6 | 3.33 |
ischemic stroke | 0.9 | 0.7 | 0.29 |
Liver Cirrhosis | 2.5 | 1.4 | 0.79 |
Long COVID | 1.8 | 1 | 0.8 |
Lung Cancer | 1.3 | 1.3 | |
Lymphoma | 0.3 | 0.3 | |
Mast Cell Issues / mastitis | 0.6 | 0.6 | |
ME/CFS with IBS | 0.1 | 0.4 | -3 |
ME/CFS without IBS | 0.5 | 0.4 | 0.25 |
membranous nephropathy | 0.1 | 0.1 | |
Menopause | 0.1 | 0.1 | |
Metabolic Syndrome | 4 | 1.8 | 1.22 |
Mood Disorders | 2.7 | 1 | 1.7 |
multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
Multiple Sclerosis | 1.2 | 1.3 | -0.08 |
myasthenia gravis | 0.3 | 0.3 | |
neuropathic pain | 0.5 | -0.5 | |
Neuropathy (all types) | 0.1 | 0.2 | -1 |
neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.3 | 0.4 | 2.25 |
NonCeliac Gluten Sensitivity | 0.4 | 0.4 | 0 |
Obesity | 2.8 | 2.2 | 0.27 |
obsessive-compulsive disorder | 1.7 | 1 | 0.7 |
Osteoarthritis | 1 | 0.5 | 1 |
Osteoporosis | 0.7 | 0.5 | 0.4 |
pancreatic cancer | 0.3 | 0.1 | 2 |
Parkinson's Disease | 2.4 | 1.5 | 0.6 |
Polycystic ovary syndrome | 2.2 | 0.9 | 1.44 |
Premenstrual dysphoric disorder | 0.1 | -0.1 | |
primary biliary cholangitis | 0.1 | 0.2 | -1 |
Primary sclerosing cholangitis | 0.7 | 0.5 | 0.4 |
Psoriasis | 1.1 | 0.6 | 0.83 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2 | 1.2 | 0.67 |
Schizophrenia | 1.1 | 0.5 | 1.2 |
scoliosis | 0.3 | 0.4 | -0.33 |
Sjögren syndrome | 0.5 | 0.5 | 0 |
Sleep Apnea | 0.2 | 0.4 | -1 |
Slow gastric motility / Gastroparesis | 0.7 | 0.7 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.9 | |
Stress / posttraumatic stress disorder | 1 | 0.5 | 1 |
Systemic Lupus Erythematosus | 2.5 | 2.5 | |
Tic Disorder | 0.1 | 0.1 | 0 |
Tourette syndrome | 0.1 | 0.4 | -3 |
Type 1 Diabetes | 1.9 | 0.5 | 2.8 |
Type 2 Diabetes | 3.4 | 1.7 | 1 |
Ulcerative colitis | 2.1 | 1.7 | 0.24 |
Unhealthy Ageing | 2.4 | 0.1 | 23 |
Vitiligo | 1.2 | 0.1 | 11 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]